LRMR
Larimar Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.83
+0.00%Aug 13, 2026, 07:33 UTC
Dimensional Fund Advisors LP increased its stake in Larimar Therapeutics, Inc. by 143.8% during the first quarter, purchasing an additional 470,968 shares, according to a recent SEC filing.
Source:Aug 4, 2026, 00:00 UTC
Larimar Therapeutics reported a net loss of $32.8 million for Q2 2026, with a diluted loss per share of $0.30, compared to a net loss of $26.2 million in Q2 2025.
Jun 29, 2026, 10:30 UTC
Larimar Therapeutics submitted the first module of its rolling Biologics License Application to the FDA for accelerated approval of nomlabofusp for Friedreich's ataxia.
Source: